Skip to main content

Day: December 9, 2019

ADLPartner : Déclaration des transactions sur actions propres réalisées du 2 au 6 décembre 2019

ADLPartnerSociété anonyme à directoire et conseil de surveillance au capital de 6 478 836 euros3, avenue de Chartres 60500 – CHANTILLY393 376 801 R.C.S. CompiègneDéclaration des transactions sur actions propres réalisées du 2 au 6 décembre 2019Présentation agrégée par jour et par marchéLe reporting détaillé est disponible sur le site internet du Groupe ADLPartner : www.adlpartner.com dans l’espace Actualités investisseurs/ Informations réglementéesRelations Investisseurs & Informations financièresTel : +33 1 41 58 72 03 – Courriel : relations.investisseurs@adlpartner.frADLPartner est cotée sur Euronext Paris – Compartiment CCodes ISIN : FR0000062978-ALP – Bloomberg : ALP FP – Reuters : ALDP.PAwww.adlpartner.comPièce jointeADLPartner_rachats_actions_09122019

Continue reading

Rallye, Foncière Euris, Finatis et Euris annoncent avoir finalisé leurs projets de plans de sauvegarde

 Rallye, Foncière Euris, Finatis et Euris annoncent avoir finalisé leurs projets de plans de sauvegarde Paris, le 9 décembre 2019 – Dans le prolongement du communiqué de presse publié le 25 septembre 2019, les sociétés Rallye1, Foncière Euris, Finatis et Euris (les « Sociétés ») annoncent avoir finalisé leurs projets de plans de sauvegarde, élaborés avec le concours des administrateurs judiciaires.Les principales modalités des propositions d’apurement du passif figurant dans ces projets de plans de sauvegarde sont décrites ci-après.RAPPEL DE LA STRUCTURE DE L’ENDETTEMENT DES SOCIETESA l’ouverture des procédures de sauvegarde, l’endettement financier brut des Sociétés (hors créances au titre d’opérations de dérivés) se décomposait comme suit :Rallye et ses FilialesFoncière EurisFinatisEurisIl est rappelé que les opérations de dérivés conclues...

Continue reading

The Scottish Salmon Company PLC: Primary Insider Transaction

Reference is made to the Company’s announcement dated 9th December regarding the transfer of treasury shares under the Company’s Share Incentive Plan (“SIP”). As a participant in the SIP James Billett, a primary insider, has purchased 127 shares of the Company at the average market price of NOK 28.25 per share.  Subsequently to this purchase Mr Billett owns 173 shares in The Scottish Salmon Company PLC.This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.

Continue reading

Final result of the rights issue in Oasmia

The final result of the rights issue in Oasmia Pharmaceutical AB (publ) (”Oasmia” or the “Company”) amounts to 198,329,980 shares subscribed for with subscription rights, which corresponds to approximately 99.5 percent of the rights issue. The remaining 945,372 shares have been allotted without subscription rights, which corresponds to approximately 0.5 percent of the offered shares.  Thus, the rights issue is fully subscribed and Oasmia receives proceeds amounting to approximately SEK 399 million before costs related to the rights issue.The final result of the rights issue in Oasmia, in which the subscription period took place from and including 20 November 2019 up to and including 4 December 2019, amounts to 198,329,980 shares subscribed for in the rights issue with subscription rights, which corresponds to approximately 99.5 percent...

Continue reading

Slutligt utfall i Oasmias företrädesemission

Det slutliga utfallet i Oasmia Pharmaceutical AB (publ) (”Oasmia” eller “Bolaget”) företrädesemission visar att 198 329 980 aktier tecknats med stöd av teckningsrätter, vilket motsvarar cirka 99,5 procent av företrädesemissionen. Återstående 945 372 aktier har tilldelats utan stöd av teckningsrätter, motsvarande cirka 0,5 procent av de erbjudna aktierna.  Företrädesemissionen i Oasmia är därmed fulltecknad och Oasmia kommer genom företrädesemissionen att tillföras cirka 399 MSEK före avdrag för emissionskostnader.Det slutliga utfallet i Oasmias företrädesemission, vars teckningsperiod löpte från och med den 20 november 2019 till och med den 4 december 2019, visar att 198 329 980 aktier tecknats i företrädesemissionen med stöd av teckningsrätter, vilket motsvarar cirka 99,5 procent av företrädesemissionen. Av dessa har 22 500 000 aktier,...

Continue reading

Earth Alive moves to the TSX Venture Exchange

MONTREAL, Dec. 09, 2019 (GLOBE NEWSWIRE) — Earth Alive Clean Technologies Inc. (CSE: EAC) (“Earth Alive” or the “Company”), is pleased to announce the commencement of trading of its common shares (symbol: EAC  – CUSIP:27031Q108) and warrants (symbol EAC.WT – CUSIP: 27031Q116 ) on the TSX Venture Exchange (“TSXV”) at the opening of trading on Tuesday  December 10, 2019.“This move from the CSE to the TSX-V comes at the end of an active year for Earth Alive and we are pleased to start the new year trading on the TSX-V, tapping into a wider investor audience as we execute our business plan.” stated Michael Warren, the Chief Executive Officer.The Company also announces that the investor relations agreement with Hybrid Financial has ended and we thank them for their services.                 About Earth Alive Clean TechnologiesEarth...

Continue reading

SEB Announces Extension of Strategic Private Placement

MISSISSAUGA, Ontario, Dec. 09, 2019 (GLOBE NEWSWIRE) — Smart Employee Benefits Inc. (“SEB” or the “Company”) (TSXV: SEB) announces that the TSX Venture Exchange (“TSXV”) has granted an extension with respect to the duration of the Company’s $20,000,000 strategic private placement financing, which financing was previously announced by press release dated November 5, 2019.  The outside date upon which final acceptance of the private placement may be granted by the TSXV has been extended to January 8, 2020. ABOUT SEBSEB is a technology company providing Business Process Automation and Outsourcing software, solutions and services to a national and global client base. SEB has a specialty growth focus in cloud enabled SaaS processing solutions for managing employer and government sponsored health benefit plans on a BPO (Business Processing...

Continue reading

North American Palladium Receives Final Order

TORONTO, Dec. 09, 2019 (GLOBE NEWSWIRE) — North American Palladium Ltd. (“NAP” or the “Company“) (TSX:PDL) (OTC PINK:PALDF) today announced that all of the required regulatory approvals have been obtained with respect to the proposed plan of arrangement (the “Arrangement”) pursuant to which an affiliate of Impala Platinum Holdings Limited (the “Purchaser“) will acquire all of the issued and outstanding common shares of the Company (the “Shares“) by way of a plan of arrangement. Under the terms of the Arrangement, shareholders of NAP other than Brookfield (defined below), will receive C$19.74 per Share in cash and Brookfield Business Partners L.P. (together with its institutional partners, collectively “Brookfield”), as the majority shareholder of NAP, will receive C$16.00 per Share...

Continue reading

DEINOVE and ESPCI Paris obtain funding from the ANR to develop the Deinodrop technology

DEINOVE et l’ESPCI Paris obtiennent un financement de l’ANRpour développer la technologie Deinodrop La technologie Deinodrop sera codéveloppée par l’ESPCI et DEINOVE pour accélérer la découverte et l’identification de bactéries productrices de nouveaux antibiotiques.L’objectif : développer une technologie de criblage et de tri à très haut débit de bactéries en gouttelettes.L’avantage : faciliter la détection d’activités antibiotiques et permettre un criblage sur cellules uniques donnant accès à des espèces réputées non-cultivables.L’ANR a accordé à Deinodrop un financement de 300k€, à la suite d’un processus de sélection très exigeant.DEINOVE (Euronext Growth Paris : ALDEI), société de biotechnologie française qui s’appuie sur une démarche d’innovation radicale pour développer des antibiotiques innovants et des ingrédients actifs...

Continue reading

DEINOVE et l’ESPCI Paris obtiennent un financement de l’ANR pour développer la technologie Deinodrop

DEINOVE et l’ESPCI Paris obtiennent un financement de l’ANRpour développer la technologie Deinodrop La technologie Deinodrop sera codéveloppée par l’ESPCI et DEINOVE pour accélérer la découverte et l’identification de bactéries productrices de nouveaux antibiotiques.L’objectif : développer une technologie de criblage et de tri à très haut débit de bactéries en gouttelettes.L’avantage : faciliter la détection d’activités antibiotiques et permettre un criblage sur cellules uniques donnant accès à des espèces réputées non-cultivables.L’ANR a accordé à Deinodrop un financement de 300k€, à la suite d’un processus de sélection très exigeant.DEINOVE (Euronext Growth Paris : ALDEI), société de biotechnologie française qui s’appuie sur une démarche d’innovation radicale pour développer des antibiotiques innovants et des ingrédients actifs...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.